Navigation Links
In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function
Date:11/7/2010

NEW YORK, Nov. 7, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months. For a third primary endpoint, the rate of DAS28-4(ESR) <2.6, a measure of disease remission, treatment with tasocitinib resulted in a numerically greater, but not statistically significant difference from placebo at three months.

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO)

In ORAL Solo, a similar frequency of adverse events was seen across all treatment groups. Serious adverse events were reported in 4.1 percent of patients. Additionally, decreases in neutrophil count and hemoglobin and an increase in cholesterol occurred by month three. These changes tended to stabilize thereafter. No new safety signals were detected.

"We are encouraged by the statistically significant and clinically meaningful improvements we observed in a proportion of patients treated with tasocitinib monotherapy in ORAL Solo," said Roy Fleischmann, MD, Clinical Professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center in Dallas.  "Further research into additional treatment options for patients with moderately to severely active RA is important, and we look forward to seeing the results of the additional Phase 3 ORAL trials of tasocitinib."

ORAL Sequel (1024), an open label, follow-up Phase 2/3 study,
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ThermoGenesis Reports 35 Percent Increase in First Quarter 2011 Revenues, Adds Strategic Advisor and Inks China Distribution Deal With Nanshan Memorial Medical Institute
2. Genoptix Reports Operating Results for the Third Quarter and First Nine Months of 2010
3. Unilife Corporation Schedules Fiscal 2011 First Quarter Conference Call For Monday, November 15, 2010
4. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
5. GREENGUARDs First Exhibit at HEALTHCARE DESIGN.10 to Help Architects and Designers Specify Healthier Products More Easily and Efficiently
6. CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance
7. Endologix Announces First Clinical Implant of Ventana™ Stent Graft
8. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
9. PAREXEL Reports First Quarter Fiscal Year 2011 Financial Results
10. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
11. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, Inc. ... vegetable-glycol solution for use in portable vaporizers, which ... active ingredients in cannabis, cannabidiol offers consumers a ... devices, and other vaporizer technology. Photo ... naturally contains 483 different compounds which are currently ...
(Date:7/11/2014)... July 11, 2014 Patient engagement has ... consequently, organizations are turning to an assortment of ... As part of this evolving approach to patient ... communicate and engage patients throughout their experiences with ... empowerment. By mapping the patient journey and employing ...
(Date:7/11/2014)... N.C. , July 11, 2014 ... approaches are evolving across industry sectors to better ... examining better ways to engage with and understand ... inform themselves and make critical purchasing decisions. ... firm, Best Practices, LLC, one area where organizations ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... SAN DIEGO, Aug. 26 CareFusion (NYSE: ... announced the national commercial launch of the AVA max® ... during kyphoplasty, a procedure for treating spinal compression fractures. ... represents a competitive breakthrough and is expected to enhance ...
... Inc. (Nasdaq: ALXA ) announced today that ... to Cypress Bioscience, Inc. (Nasdaq: CYPB).  The Staccato ... system designed to help people stop smoking.  The ... a well-validated smoking cessation approach by delivering nicotine via ...
Cached Medicine Technology:CareFusion Announces National Launch of Spinal Fracture Device 2CareFusion Announces National Launch of Spinal Fracture Device 3Alexza's Staccato® Nicotine Licensed to Cypress Bioscience 2Alexza's Staccato® Nicotine Licensed to Cypress Bioscience 3Alexza's Staccato® Nicotine Licensed to Cypress Bioscience 4
(Date:7/11/2014)... 11, 2014 Ticket Down reports that tickets ... and 3rd place World Cup Match between Brazil and ... will take place on Saturday, July 12th at Estadio Nacional ... Finals will take place on Sunday, July 13th at Estadio ... All tickets for the 2014 World Cup are guaranteed to ...
(Date:7/11/2014)... York (PRWEB) July 11, 2014 ... , filed against Johnson & Johnson’s Ethicon Inc. ... Liebhard LLP notes that the Texas Attorney General’s ... company’s marketing of surgical mesh products used to ... According to a report from kens5.com, the probe ...
(Date:7/11/2014)... July 11, 2014 Butler Mobility has recently ... Inclined Platform Lifts . Previously the two standard colors ... new beautiful earth tone colors as standard colors at no ... in the home but will enhance the beauty of the ... any home color scheme or individual décor. , The new ...
(Date:7/11/2014)... (HealthDay News) -- Reducing the number of deer in ... disease and other tick-borne infections among people, new research ... be manipulated to reduce human interactions with deer, infected ... the researchers wrote. White-tailed deer are the primary ... to people. The study included nearly all the ...
(Date:7/11/2014)... -- People with the lowest incomes may have a higher ... a new study suggests. People with PAD have narrowing ... often the legs. The condition causes leg pain and is ... body. People with PAD have a higher risk for heart ... people with PAD who took part in the U.S. National ...
Breaking Medicine News(10 mins):Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:Poor More Prone to Leg Circulation Trouble 2
... Young adults whose mothers experienced psychological trauma during ... Irvine-led study found. The researchers discovered that this ... regions that control cell aging processes. The study results, ... of the National Academy of Sciences , point to ...
... 11th leading cause of death in the United States. Every ... Sadly, each year tens of thousands die by suicide. While ... warning signs exist. Often a simple question from a family ... and treatment. A new review in the August ...
... CHAPEL HILL, N.C. - Joanne M. Jordan, MD, MPH, director ... North Carolina at Chapel Hill, has received the 2011 Distinguished ... (RSS). The purpose of the award is to recognize ... enhancement of rural life and rural people. For more than ...
... cell phones have led to preventive policies in France, Israel, ... the health risks associated with exposure to the radiation energy ... of the Environmental Health Trust, in a timely and informative ... by Mary Ann Liebert, Inc. The interview is available free ...
... HealthDay Reporter , MONDAY, Aug. 1 (HealthDay News) -- ... acid DHA during pregnancy, their babies have fewer cold symptoms ... and 3 months of age, about 38 percent of babies ... symptoms, compared to about 45 percent of the babies whose ...
... , MONDAY, Aug. 1 (HealthDay News) -- Despite the ... -- which can be done at home or in day ... However, colon cleansing can cause serious side effects ranging ... the report say. Colon cleansing -- also called colonic ...
Cached Medicine News:Health News:UCI-led study links prenatal exposure to stress with accelerated cell aging 2Health News:Mayo Clinic: Primary physicians may hold key to suicide prevention 2Health News:Dr. Joanne Jordan receives Distinguished Service to Rural Life Award 2Health News:Prenatal Omega-3 Fatty Acid Supplements May Cut Babies' Colds 2Health News:Prenatal Omega-3 Fatty Acid Supplements May Cut Babies' Colds 3Health News:Colon Cleansing Has No Health Benefit, May Harm: Report 2
... grafting or creation of a vascular access, ... is of the utmost importance in many ... for those seeking a high-precision tunneling instrument. ... risk of twisting or kinking for more ...
... have met the challenges of the ... exceptional performance and quality, they have ... worldwide. These grafts require no preclotting, ... infection, and ensure utmost thrombectomy safety. ...
... the challenges of the most demanding vascular ... exceptional performance and quality, they have earned ... grafts require no preclotting, resist dilatation and ... thrombectomy safety. Gore vascular grafts are also ...
... the newest vascular graft offering from W. ... vascular surgical products for more than two ... and compression problems that can lead ... all of the benefits of a ring ...
Medicine Products: